Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Disclosure information not submitted.
SP05A - Outcomes in Patients (pts) with Advanced Basal Cell Carcinoma (aBCC) Who Discontinued First-line (1L) Hedgehog Inhibitors (HHI) Systemic Treatment (Tx) in a US Community Oncology Setting: A Retrospective Observational Study
Tuesday, August 24, 20213:30 PM – 4:45 PM US Eastern Time